Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...

On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.

Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

The FDA approved the company's COVID vaccine in October 2023. The stock has gained 111% in the year to date, while the S&P 500 SPX has gained 22%. This content was created by MarketWatch, which is ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...